1-6 of 6
Lee Bowman
Close
Sort by
Journal Articles

Outcomes for Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States and Japan: A Study of Two Real-World Databases

Shinya Rai, Lisa M. Hess, Yongmei Chen, Lee Bowman, Paolo B. Abada, Heiko Konig, Richard A. Walgren, Yoshinori Tanizawa, Zhihong Cai, Masaomi Tajimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 4523.
https://doi.org/10.1182/blood-2021-148265
Published: 2021
Journal Articles

Frequency, Health Care Resource Use (HCRU), and Costs Associated With Skeletal Related Events (SREs) In US Patients With Multiple Myeloma (MM)

Emily Nash Smyth, PharmD, Ilaria Conti, MD, PhD, James Wooldridge, MD, Lee Bowman, PhD, Li Li, PhD, David Nelson, MS, Jin Xie, MS, Daniel E Ball, DrPH
Journal: Blood
Blood (2013) 122 (21): 2968.
https://doi.org/10.1182/blood.V122.21.2968.2968
Published: 2013
Journal Articles

Comparison of Out-of-Pocket Costs and Quality of Life (QOL) for Patients (pts) with Hodgkin’s Disease (HD), Indolent Non-Hodgkin’s Lymphoma (INHL) and Aggressive Non-Hodgkin’s Lymphoma (ANHL).

Narissa J. Nonzee, BS, Sheila O. Brown, RN BSN MHSA, Chih-Hung Chang, PhD, Andrew M. Evens, DO, Leo I. Gordon, MD, Jane N. Winter, MD, Lee Bowman, PhD, Lucie Kutikova, PhD, Charles L. Bennett, MD, PhD, MPP
Journal: Blood
Blood (2006) 108 (11): 3332.
https://doi.org/10.1182/blood.V108.11.3332.3332
Published: 2006
Journal Articles

Development of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma Clinical Research: The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym).

David Cella, PhD, Kimberly Webster, MA, John Cashy, PhD, Lucie Kutikova, PhD, Michael F. Burgess, MD, Boris K. Lin, MD, Lee Bowman, PhD, Astra M. Liepa, PharmD, Janine E. Gauthier, PhD, Stephanie A. Gregory, MD, Stephen A. Johnson, MD, Bruce D. Cheson, MD, on Behalf of the FACT-Lym Development Group
Journal: Blood
Blood (2005) 106 (11): 750.
https://doi.org/10.1182/blood.V106.11.750.750
Published: 2005
Journal Articles

Comparison of Out-of-Pocket Costs for Patients (pts) with Hodgkin’s Disease (HD), Indolent Non-Hodgkin’s Lymphoma (INHL) and Aggressive Non-Hodgkin’s Lymphoma (ANHL).

Kathryn McCaffrey, BA, Matthew Fisher, Lucie Kutikova, PhD, Lee Bowman, PhD, Andrew Evens, DO, Leo Gordon, MD, Heather Auto, Charles Bennett, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2241.
https://doi.org/10.1182/blood.V106.11.2241.2241
Published: 2005
Journal Articles

Developing National Estimates of the Out-of-Pocket Costs of Cancer: The Importance of Including Patients with Lymphoma.

Kathryn R. McCaffrey, B.A., Kenneth R. Carson, MD, Lucie Kutikova, Ph.D., Matt Fisher, Simon Pickard, Ph.D., Glen Schumock, PharmD, MBA, Lee Bowman, Ph.D., Charles L. Bennett, MD, Ph.D., MPP
Journal: Blood
Blood (2004) 104 (11): 3138.
https://doi.org/10.1182/blood.V104.11.3138.3138
Published: 2004